Comparative Pharmacology
Head-to-head clinical analysis: KYXATA versus SELARSDI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KYXATA versus SELARSDI.
KYXATA vs SELARSDI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective endothelin receptor antagonist (ERA) targeting endothelin type A (ETA) receptors, reducing pulmonary vascular resistance and remodeling in pulmonary arterial hypertension (PAH).
Selective angiotensin II type 1 receptor antagonist that blocks vasoconstriction and aldosterone secretion.
KYXATA (landiolol) intravenously: For atrial fibrillation/flutter (AF/AFL) with rapid ventricular rate: Initial intravenous bolus dose of 0.125 mg/kg over 1 minute, followed by continuous intravenous infusion of 0.05 to 0.2 mg/kg/min, titrated to heart rate control. Maximum infusion rate is 0.4 mg/kg/min.
Intravenous 0.15 mg/kg every 8 hours for 14 days.
None Documented
None Documented
Terminal elimination half-life is 12–15 hours in adults with normal renal function; extends to 22–30 hours in moderate renal impairment (CrCl 30–50 mL/min) and up to 48 hours in severe impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 11 hours (range 7–15 hours), supporting twice-daily dosing; half-life may be prolonged in renal impairment.
Renal excretion accounts for approximately 70% of elimination (60% unchanged, 10% as metabolites); biliary/fecal excretion accounts for 25% (primarily as metabolites); minor metabolic clearance (5%) via CYP3A4.
Primarily renal excretion of unchanged drug (approximately 70%) and glucuronide conjugate (approximately 20%); biliary/fecal elimination accounts for less than 10%.
Category C
Category C
Unknown
Unknown